Controlled Release Solid Dosage Forms Using Combinations of (meth)acrylate Copolymers

REFERENCES

• J McGinity, and Marcel. (1997). Aqueous polymeric coatings for pharmaceutical dosage forms.
   Google Scholar
• CG Cameron, and JW McGinity. (1987). Controlled-release theophylline tablet formulations containing acrylic resins 2. Combination resin formulations. Drug Develop. Industr. Pharm. 13 (8):1409–1427.
   Google Scholar
• I. Agabeyoglu. (1985). Studies on sustained release I: The biopharmaceutical design and production of an inert matrix type Sulfamethizole tablet, employing polymethylmethacrylate. Drug Develop. Industr. Pharm. 11 (11):2021–2041.
   Google Scholar
• Y-H Kao, C.-H Liu, T.D Sokolosky, M.-T Sheu, and et al. (1994). The influence of Eudragit S-100 on the release of Chlorphaniramine maleate from matrix tablets containing Eudragit RS-PM. Chinese Pharmaceut. J. 46:257–267.
   Google Scholar
• SY Lin, and YH Kao. (1990). Effect of Eudragit resins and dibasic calcium-phosphate on the compaction and dissolution behavior of directly compressible controlled-release theophylline tablet. Drug Develop. Industr Pharm. 16 (5):855–874.
   Google Scholar
• M Fernández-Arévalo, AM Rabasco Alvarez, MA Holgado Villafuerte, JM Gines Dorado, and et al. (1991). Inert matrix tablets as a controlled release dosage form for carteolol hydrochloride. Eur. J. Pharmaceut. Biopharmaceut. 37 (3):147–153.
   Google Scholar
• P de Haan, and CF Lerk. (1986). The megaloporous system: A novel principle for zero-order drug delivery II. A model for the mechanism of drug delivery. Int. J. Pharmaceut. 34 (1–2):57–66.
   Google Scholar
• M Fernandez-Arevalo, MA Holgado-Villafuerte, JM Gines-Dorado, AM Rabasco-Alvarez, and et al. (1993). Effects of different fillers and wetting liquids on the dissolution behavior of carteolol hydrochloride controlled release inert matrix tablets. Int. J. Pharmaceut. 95 (1–3):117–125.
   Google Scholar
• I Ozguney, G Ertan, and T. Guneri. (2004). Dissolution characteristics of megaloporous tablets prepared with two kinds of matrix granules. Farmaco 59 (7):549–555.
   PubMedGoogle Scholar
• HMA Zerquera, EB Benitez, and RD Leyva. (1983). Sustained-release of drugs by inclusion in plastic matrices. 1. Dexchlorpheniramine maleate. J. Pharmac. De Belgique. 38 (6):315–319.
   PubMedGoogle Scholar
• GE Peck, NR Anderson, and GS Banker. Principles of improved tablet production system design Pharmaceutical Dosage Forms: Tablets HA Lieberman, L Lachman, and JB Schwartz. Marcel Dekker, New York, (1990)1–74.
   Google Scholar
• T Niskanen, J Yliruusi, M Niskanen, O Kontro, and et al. (1990). Granulation of potassium chloride in istrumented fluidized bed granulator – part I: Effect of flow rate. Acta Pharmac Fennica. 99 (1):13–22.
   Google Scholar
• M Bhattacharyya, SC Mandal, and BK Gupta. (1992). Controlled delivery of bromhexine hydrochloride using rate-controlling polymers. STP Pharma Sci. 2 (6):481–487.
   Google Scholar
• MP Oth, and AJ Moes. (1989). Sustained release solid dispersions of indomethacin with Eudragit RS and RL. Int. J. Pharmaceut. 55 (2–3):157–164.
   Google Scholar
• H-U. Petereit. Matrix tablets, influence process technologies on drug release, in APV Seminar 102. , Stuttgart, (1994).
   Google Scholar
• KH Bauer, K Lehmann, HP Osterwald, G Rothgang, and et al. Coated pharmaceutical dosage forms. Fundamentals, manufacturing techniques, biopharmaceutical aspects, test methods and raw materials. Medpharm GmbH Scientific Publishers, Stuttgart, (1998).
   Google Scholar
• M. Mollan. Historical overview Pharmaceutical Extrusion Technology, I Ghebre- Sellassie, and C. Martin. Marcel Dekker, New York, (2003)1–18.
   Google Scholar
• MR Abbaspour, F Sadeghi, and A. Garekani. (2005). Preparation and characterization of ibuprofen pellets based on Eudragit RS PO and RL PO or their combination. Int. J Pharmaceut. 303 (1–2):88–94.
   PubMedGoogle Scholar
• M Fukuda, NA Peppas, and JW McGinity. (2006). Floating hot-melt extruded tablets for gastroretentive controlled drug release system. J. Controlled Release. 115 (2):121–129.
   PubMedGoogle Scholar
• A Karnachi, and M. Khan. (1996). Box-behnken design for the optimization of formulation variables of indomethacin coprecipitates with polymer mixtures. Int. J. Pharmaceut. 131 (1):9–17.
   Google Scholar
• KA Mehta, MS Kislalioglu, W Phuapradit, AW Malick, NH Shah, and et al. (2001). Release performance of a poorly soluble drug from a novel, Eudragit®-based multi-unit erosion matrix. Int. J. Pharmaceut. 213 (1–2):7–12.
   PubMedGoogle Scholar
• KA Mehta, MS Kislalioglu, W Phuapradit, AW Malick, NH Shah, and et al. (2002). Effect of formulation and process variables on matrix erosion and drug release from a multiunit erosion matrix of a poorly soluble drug. Pharmaceut. Technol. 26 (2):26–34.
   Google Scholar
• K Amighi, J Timmermans, J Puigdevall, E Baltes, AJ Moës, and et al. (1998). Peroral sustained-release film-coated pellets as a means to overcome physicochemical and biological drug-related problems. I. In vitro development and evaluation. Drug Develop. Industr. Pharm. 24 (6):509–515.
   PubMed Web of Science ®Google Scholar
• WJ Zheng, and JW McGinity. (2003). Influence of Eudragit® NE 30 D blended with Eudragit® L 30 D-55 on the release of phenylpropanolamine hydrochloride from coated pellets. Drug Develop Indust. Pharm. 29 (3):357–366.
   PubMed Web of Science ®Google Scholar
• VK Gupta, TE Beckert, NJ Deusch, M Hariharan, JC Price, and et al. (2002). Investigation of potential ionic interactions between anionic and cationic polymethacrylates of multiple coatings of novel colonic delivery system. Drug Develop. Indust. Pharm. 28 (2):207–215.
   PubMedGoogle Scholar
• CB Wu, and JW McGinity. (2003). Influence of an enteric polymer on drug release rates of theophylline from pellets coated with Eudragit® RS 30D. Pharmaceut. Develop. Technol. 8 (1):103–110.
   PubMed Web of Science ®Google Scholar
• A Dashevsky, K Kolter, and R. Bodmeier. (2004). Compression of pellets coated with various aqueous polymer dispersions. Int. J. Pharmaceut. 279 (1–2):19–26.
   PubMedGoogle Scholar
• A Ceballos, M Cini, F Maestrelli, G Corti, P. Mura, and et al. (2005). Influence of formulation and process variables on in vitro release of theophylline from directly-compressed Eudragit matrix tablets. Il Farmaco 60 (11–12):913–918.
   PubMedGoogle Scholar
• RI Moustafine, TV Kabonova, VA Kemenova, G. Van den Mooter, and et al. (2005). Characteristics of interpolyelectrolyte complexes of Eudragit E100 with Eudragit L100. J. Controlled Release. 103 (1):191–198.
   PubMed Web of Science ®Google Scholar
• RI Moustafine, IM Zaharov, and VA Kemenova. (2006). Physicochemical characterization and drug release properties of Eudragit® E PO/Eudragit® L 100-55 interpolyelectrolyte complexes. Eur. J. Pharmaceut. Biopharmaceut. 63 (1):26–36.
   PubMed Web of Science ®Google Scholar